Core Viewpoint - Yuan Dong Biotech (688513) has announced the initiation of Phase I clinical trials for its innovative chemical drug EP-0226, aimed at treating neuropathic pain, in collaboration with the Shanghai Institute of Materia Medica and the Zhongke Zhongshan Drug Innovation Research Institute [1] Group 1 - The first subject has been dosed in the clinical trial for EP-0226 [1] - Preclinical studies indicate that EP-0226 demonstrates superior target selectivity, in vivo analgesic activity, and efficacy compared to the approved drug pregabalin [1] - The safety profile of EP-0226 is reported to be good, suggesting it may provide a safe and effective treatment option for patients suffering from neuropathic pain [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has initiated Phase I clinical trials for its innovative drug EP-0226, developed in collaboration with the Shanghai Institute of Materia Medica and Zhongke Zhongshan Drug Innovation Research Institute, aimed at treating neuropathic pain [1] Group 1: Drug Development - EP-0226 is a novel calcium channel (Cav2.2) modulator designed to treat neuropathic pain by binding to the calcium channel α2δ subunit, reducing calcium influx in neurons, and consequently decreasing the release of excitatory neurotransmitters such as glutamate and norepinephrine [1] - Preclinical studies indicate that EP-0226 demonstrates superior target selectivity, analgesic activity, and efficacy compared to the approved drug pregabalin, with good safety profiles, potentially offering a new safe and effective treatment option for patients with neuropathic pain [1]

Core Viewpoint - The latest research published in Nature suggests a novel approach to alleviate pain caused by peripheral neuropathy by providing healthy mitochondria to damaged neurons, potentially offering new treatment strategies for neuropathic pain [4][17]. Group 1: Research Findings - The study indicates that supplementing mitochondria can significantly reduce pain associated with diabetic neuropathy and chemotherapy-induced nerve damage, with pain relief lasting up to 48 hours [5]. - The research demonstrates that satellite glial cells (SGC) can transfer mitochondria to primary sensory neurons through tunneling nanotubes, which is crucial for maintaining neuronal function [9][10]. - In diabetic patients, a decrease in MYO10 protein expression in SGC correlates with reduced mitochondrial transfer to neurons, suggesting a mechanism for neuropathic pain [12]. Group 2: Implications for Treatment - The findings provide new insights into the role of peripheral glial cells in diabetic small fiber neuropathy and propose a new strategy for treating neuropathic pain [17]. - The potential for using SGC to deliver MYO10-dependent protective effects against peripheral neuropathy highlights a promising avenue for therapeutic development [12].